332 related articles for article (PubMed ID: 28542693)
1. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.
Schönbach EM; Wolfson Y; Strauss RW; Ibrahim MA; Kong X; Muñoz B; Birch DG; Cideciyan AV; Hahn GA; Nittala M; Sunness JS; Sadda SR; West SK; Scholl HPN;
JAMA Ophthalmol; 2017 Jul; 135(7):696-703. PubMed ID: 28542693
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months: ProgStar Report No. 13.
Schönbach EM; Strauss RW; Muñoz B; Wolfson Y; Ibrahim MA; Birch DG; Zrenner E; Sunness JS; Ip MS; Sadda SR; West SK; Scholl HPN;
JAMA Ophthalmol; 2020 Jul; 138(7):772-779. PubMed ID: 32463436
[TBL] [Abstract][Full Text] [Related]
3. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.
Strauss RW; Ho A; Muñoz B; Cideciyan AV; Sahel JA; Sunness JS; Birch DG; Bernstein PS; Michaelides M; Traboulsi EI; Zrenner E; Sadda S; Ervin AM; West S; Scholl HP;
Ophthalmology; 2016 Apr; 123(4):817-28. PubMed ID: 26786511
[TBL] [Abstract][Full Text] [Related]
4. Microperimetry Features of Geographic Atrophy Identified With En Face Optical Coherence Tomography.
Pilotto E; Convento E; Guidolin F; Abalsamo CK; Longhin E; Parrozzani R; Midena E
JAMA Ophthalmol; 2016 Aug; 134(8):873-9. PubMed ID: 27253760
[TBL] [Abstract][Full Text] [Related]
5. Multimodal analysis of the Preferred Retinal Location and the Transition Zone in patients with Stargardt Disease.
Verdina T; Greenstein VC; Sodi A; Tsang SH; Burke TR; Passerini I; Allikmets R; Virgili G; Cavallini GM; Rizzo S
Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1307-1317. PubMed ID: 28365912
[TBL] [Abstract][Full Text] [Related]
6. Differential Disease Progression in Atrophic Age-Related Macular Degeneration and Late-Onset Stargardt Disease.
Lindner M; Lambertus S; Mauschitz MM; Bax NM; Kersten E; Lüning A; Nadal J; Schmitz-Valckenberg S; Schmid M; Holz FG; Hoyng CB; Fleckenstein M;
Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):1001-1007. PubMed ID: 28288486
[TBL] [Abstract][Full Text] [Related]
7. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease.
Melillo P; Testa F; Rossi S; Di Iorio V; Orrico A; Auricchio A; Simonelli F
Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT247-52. PubMed ID: 27409479
[TBL] [Abstract][Full Text] [Related]
8. Macular function and morphologic features in juvenile stargardt disease: longitudinal study.
Testa F; Melillo P; Di Iorio V; Orrico A; Attanasio M; Rossi S; Simonelli F
Ophthalmology; 2014 Dec; 121(12):2399-405. PubMed ID: 25097154
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5.
Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Mohand-Said S; Cideciyan AV; Birch D; Hariri AH; Nittala MG; Sadda S; Scholl HPN;
JAMA Ophthalmol; 2017 Jul; 135(7):687-695. PubMed ID: 28542697
[TBL] [Abstract][Full Text] [Related]
10. Morpho-functional correlation of fundus autofluorescence in Stargardt disease.
Parodi MB; Iacono P; Triolo G; La Spina C; Zucchiatti I; Cicinelli MV; Borrelli E; Manitto MP; Martina E; Bandello F
Br J Ophthalmol; 2015 Oct; 99(10):1354-9. PubMed ID: 25837607
[TBL] [Abstract][Full Text] [Related]
11. Faster Sensitivity Loss around Dense Scotomas than for Overall Macular Sensitivity in Stargardt Disease: ProgStar Report No. 14.
Schönbach EM; Strauss RW; Ibrahim MA; Janes JL; Birch DG; Cideciyan AV; Sunness JS; Muñoz B; Ip MS; Sadda SR; Scholl HPN;
Am J Ophthalmol; 2020 Aug; 216():219-225. PubMed ID: 32222369
[TBL] [Abstract][Full Text] [Related]
12. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).
Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Cideciyan AV; Audo I; Birch DG; Hariri AH; Nittala MG; Sadda S; West S; Scholl HPN;
JAMA Ophthalmol; 2017 Nov; 135(11):1232-1241. PubMed ID: 29049437
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric Inter-Eye Progression in Stargardt Disease.
Lambertus S; Bax NM; Groenewoud JM; Cremers FP; van der Wilt GJ; Klevering BJ; Theelen T; Hoyng CB
Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6824-6830. PubMed ID: 28002570
[TBL] [Abstract][Full Text] [Related]
14. Visual Acuity Change over 12 Months in the Prospective Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: ProgStar Report Number 6.
Kong X; Strauss RW; Cideciyan AV; Michaelides M; Sahel JA; Munoz B; Ahmed M; Ervin AM; West SK; Cheetham JK; Scholl HPN;
Ophthalmology; 2017 Nov; 124(11):1640-1651. PubMed ID: 28549516
[TBL] [Abstract][Full Text] [Related]
15. The Progression of Stargardt Disease Using Volumetric Hill of Vision Analyses Over 24 Months: ProgStar Report No.15.
Schönbach EM; Janeschitz-Kriegl L; Strauss RW; Cattaneo MEGV; Fujinami K; Birch DG; Cideciyan AV; Sunness JS; Weleber RG; Ip MS; Sadda SR; Scholl HPN;
Am J Ophthalmol; 2021 Oct; 230():123-133. PubMed ID: 33951446
[TBL] [Abstract][Full Text] [Related]
16. Quantification of peripapillary sparing and macular involvement in Stargardt disease (STGD1).
Burke TR; Rhee DW; Smith RT; Tsang SH; Allikmets R; Chang S; Lazow MA; Hood DC; Greenstein VC
Invest Ophthalmol Vis Sci; 2011 Oct; 52(11):8006-15. PubMed ID: 21873672
[TBL] [Abstract][Full Text] [Related]
17. Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease (SMART) Study: Design and Baseline Characteristics (Report No. 1).
Strauss RW; Kong X; Bittencourt MG; Ho A; Jha A; Schönbach EM; Ahmed MI; Muñoz B; Ervin AM; Michaelides M; Birch DG; Sahel JA; Sunness JS; Zrenner E; Bagheri S; Ip M; Sadda S; West S; Scholl HPN;
Ophthalmic Res; 2019; 61(1):36-43. PubMed ID: 29940588
[TBL] [Abstract][Full Text] [Related]
18. Visual Acuity Change Over 24 Months and Its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease: ProgStar Study Report No. 10.
Kong X; Fujinami K; Strauss RW; Munoz B; West SK; Cideciyan AV; Michaelides M; Ahmed M; Ervin AM; Schönbach E; Cheetham JK; Scholl HPN;
JAMA Ophthalmol; 2018 Aug; 136(8):920-928. PubMed ID: 29902293
[TBL] [Abstract][Full Text] [Related]
19. Foveal sparing in Stargardt disease.
van Huet RA; Bax NM; Westeneng-Van Haaften SC; Muhamad M; Zonneveld-Vrieling MN; Hoefsloot LH; Cremers FP; Boon CJ; Klevering BJ; Hoyng CB
Invest Ophthalmol Vis Sci; 2014 Oct; 55(11):7467-78. PubMed ID: 25324290
[TBL] [Abstract][Full Text] [Related]
20. Impact of segmentation density on spectral domain optical coherence tomography assessment in Stargardt disease.
Velaga SB; Nittala MG; Jenkins D; Melendez J; Ho A; Strauss RW; Scholl HP; Sadda SR
Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):549-556. PubMed ID: 30613916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
